Drug Shortage Report for NORDITROPIN NORDIFLEX
| Report ID | 178319 |
| Drug Identification Number | 02334852 |
| Brand name | NORDITROPIN NORDIFLEX |
| Common or Proper name | NORDITROPIN NORDIFLEX |
| Company Name | NOVO NORDISK CANADA INC |
| Market Status | MARKETED |
| Active Ingredient(s) | SOMATROPIN |
| Strength(s) | 5MG |
| Dosage form(s) | SOLUTION |
| Route of administration | SUBCUTANEOUS SUBCUTANEOUS |
| Packaging size | EA |
| ATC code | H01AC |
| ATC description | ANTERIOR PITUITARY LOBE HORMONES AND ANALOGUES |
| Reason for shortage | Demand increase for the drug. |
| Anticipated start date | 2023-06-01 |
| Actual start date | |
| Estimated end date | 2023-08-30 |
| Actual end date | |
| Shortage status | Anticipated shortage |
| Updated date | 2022-12-14 |
| Company comments | Norditropin® NordiFlex® 15 mg will continue to be available to Canadian patients to ensure all patients currently taking Norditropin® can remain on treatment. |
| Health Canada comments | |
| Tier 3 Status | No |
| Contact Address | 101-2476 ARGENTIA ROAD MISSISSAUGA, ONTARIO CANADA L5N 6M1 |
| Company contact information | 1 800 465 4334 |
Version History
Click on "Compare" below to view the full report history and compare to other versions.
| Version Number | Date Updated | Language | |
|---|---|---|---|
| v2 | 2022-12-14 | French | Compare |
| v1 | 2022-12-14 | English | Compare |
Showing 1 to 2 of 2